이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도에서 중증 판상 건선 환자 치료에 대한 GNR-068(우스테키누맙 바이오시밀러) 및 Stelara®의 효능 및 안전성 연구

2026년 9월 16일 업데이트: AO GENERIUM

GNR-068(45mg) 및 Stelara®(45mg)의 효능 및 안전성에 대한 다기관 국제 단일 맹검 무작위 비교 임상 연구 및 중등도 및 중등도 및 Stelara®(45mg) 환자에서 GNR-068의 안전성, 내약성 및 장기 유효성 평가 심각한 형태의 판상 건선

This is a randomized single-blind comparative parallel group efficacy and safety study of ustekinumab biosimilar GNR-068 (45 mg) and reference product Stelara® (45 mg) in the treatment of patients with moderate and severe forms of plaque psoriasis. Participants received a subcutaneous dose of ustekinumab 45 mg (GNR-068 or Stelara®) at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg. For patients with partially respond to the initial regimen the regimen can be adjusted.

연구 개요

상세 설명

The drug GNR-068 (INN: ustekinumab) is being developed as a biosimilar to the drug Stelara®, solution for subcutaneous administration (Silag AG, Switzerland).

Preclinical studies and early phase clinical studies suggest that interleukins-12 (IL-12) and -23 (IL-23), two molecules that are part of the communication network in the immune system, may play an important role in psoriasis. Ustekinumab is a monoclonal antibody directed against IL-12 and IL-23. This is a randomized, single blind, parallel-group, multicenter study to determine the effectiveness and safety of ustekinumab biosimilar GNR-068 administered subcutaneously as compared with Stelara® in patients with moderate to severe plaque-type psoriasis. Patients receive GNR-068 45 mg or Stelara 45 mg administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28, thereafter until week 52 all patients receive GNR-068. For patients who partially respond to the initial regimen, the dose can be adjusted to 90 mg and then the interval can be adjusted to every 8 weeks. The study included a screening period, comparative treatment period, non-comparative treatment period, follow up period. Allocation of patients to treatment groups was carried out by randomization in a ratio of 1:1. 422 patients (211 to each study groups) were randomized.

연구 유형

중재적

등록 (실제)

422

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Barnaul
      • Barnaul, Barnaul, 러시아 제국, 656038
        • Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation
    • Chelyabinsk Oblast
      • Chelyabinsk, Chelyabinsk Oblast, 러시아 제국, 454048
        • State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"
      • Chelyabinsk, Chelyabinsk Oblast, 러시아 제국, 454126
        • Limited Liability Company "Ecology of Health"
    • Ekaterinburg
      • Yekaterinburg, Ekaterinburg, 러시아 제국, 620076
        • State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"
    • Izhevsk
      • Izhevsk, Izhevsk, 러시아 제국, 426061
        • Limited Liability Company "Alliance Biomedical - Ural Group"
    • Kirov Oblast
      • Kirov, Kirov Oblast, 러시아 제국, 610027
        • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation (FSBEI HE Kirov State Medical University of the Ministry of Health of Russia))
    • Leningradskaya Oblast'
      • Murino, Leningradskaya Oblast', 러시아 제국, 188678
        • Limited Liability Company "Available Polyclinic"
    • Lipetsk Oblast
      • Lipetsk, Lipetsk Oblast, 러시아 제국, 398005
        • State health care institution "Regional Dermatovenerological Dispensary"
    • Moscow
      • Moscow, Moscow, 러시아 제국, 105554
        • Limited Liability Company "OLLA-MED"
      • Moscow, Moscow, 러시아 제국, 115522
        • Federal State Budgetary Institution "Research Institute of Rheumatology named after V.A. Nasonova"
      • Moscow, Moscow, 러시아 제국, 117321
        • Limited Liability Company "Firma ORIS"
      • Moscow, Moscow, 러시아 제국, 119071
        • State budgetary healthcare institution of the city of Moscow "Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Health Department"
      • Moscow, Moscow, 러시아 제국, 127006
        • Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation (FSBEI HE "Russian University of Medicine" of the Ministry of Health of Russia)
      • Moscow, Moscow, 러시아 제국, 129110
        • State budgetary healthcare institution of the Moscow region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
    • Moscow Oblast
      • Korolyov, Moscow Oblast, 러시아 제국, 141060
        • Limited Liability Company "Family Clinic No. 4"
    • Novosibirsk Oblast
      • Novosibirsk, Novosibirsk Oblast, 러시아 제국, 630099
        • Limited Liability Company "Medical Center "Healthy Family"
    • Orenburg Oblast
      • Orenburg, Orenburg Oblast, 러시아 제국, 460018
        • Federal State Budgetary Educational Institution of Higher Education Orenburg State Medical University of the Ministry of Health of Russia
    • Ryazan Oblast
      • Ryazan, Ryazan Oblast, 러시아 제국, 390046
        • State budgetary institution of the Ryazan region "Regional clinical dermatovenerological dispensary"
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 191123
        • Limited Liability Company "Clinic of Skin Diseases Pierre Wolkenstein"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 191123
        • Limited Liability Company "International Medical Center"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 192148
        • Limited Liability Company "Medical Technologies" LLC "Medical Technologies"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 194156
        • Limited Liability Company "Health Energy"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 194214
        • Limited Liability Company "Interleukin"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 196084
        • Limited Liability Company "Institute of Medical Research"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 196143
        • Limited Liability Company "Research Center Eco-Safety"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 196158
        • Limited Liability Company "PiterKlinika"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 196191
        • Limited Liability Company "ArsVite North-West"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 196240
        • Limited Liability Company "Curator"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 196603
        • Private medical institution "Euromedservice"
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 197136
        • Limited Liability Company "MEDINET"
    • Saratov Oblast
      • Saratov, Saratov Oblast, 러시아 제국, 410012
        • Limited Liability Company "SB Clinic of Cosmetology"
    • Smolensk Oblast
      • Smolensk, Smolensk Oblast, 러시아 제국, 214031
        • Regional state budgetary healthcare institution "Smolensk Dermatovenerological Dispensary"
    • Tatarstan Republic
      • Kazan', Tatarstan Republic, 러시아 제국, 420111
        • Limited Liability Company Medical Center "Azbuka Health"
    • Ulyanovsk Oblast
      • Ulyanovsk, Ulyanovsk Oblast, 러시아 제국, 432063
        • State Budgetary Healthcare Institution Ulyanovsk area Clinical Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Written informed consent to participate in the study.

  • Men and women 18-75 years of age, inclusive, at the time of signing the informed consent form.

  • Patients diagnosed with plaque psoriasis at least 6 months before screening:

    1. Moderate or severe form of the disease, which is defined as: PASI index ≥12, body surface area (BSA) affected by plaque psoriasis, ≥10%, PGA scale score ≥3 (on a scale from 0 to 4).
    2. Presence of indications for systemic therapy, defined as inadequate control of the disease against the background of: local treatment (including local glucocorticosteroids) and/or phototherapy and/or lack of clinical effect from the use of other systemic methods.
    3. It is acceptable to carry out basic therapy for psoriatic arthritis at a stable dose for ≥ 4 weeks before screening: prednisolone at a dose of ≤10 mg per day, NSAIDs, methotrexate at a dose of ≤15 mg per week, sulfasalazine at a dose of 2.0 g per day.
  • Body weight less than 100 kg.

  • If it is necessary to take drugs that worsen the course of psoriasis (beta blockers, calcium channel blockers, lithium drugs, etc.): a stable dose of these drugs for ≥ 4 weeks before randomization.

  • Consent of women of childbearing age, women in menopause lasting less than 2 years and male patients to comply with adequate methods of contraception throughout the study and for 3 months after the end of ustekinumab therapy.

  • Patients should not be donors of blood or its components 30 days before inclusion in the study and not become donors of blood or its components throughout the study and for 3 months after its completion.

Exclusion Criteria:

  • Types of psoriasis other than plaque, except for concomitant psoriatic arthritis.
  • History of therapy with ustekinumab or any therapy aimed at IL-12 or IL-23 (briakinumab, guselkumab, tildrakizumab).
  • Therapy with TNF-alpha inhibitors or any other genetically engineered biological drugs within 3 months before randomization.
  • Conducting other systemic therapies (including cyclosporine, acitretin, methotrexate, UV and PUVA therapy) within 1 month before randomization.
  • Treatment with leflunomide for 6 months before randomization.
  • Spread of the inflammatory process involving the gastrointestinal tract (inflammatory bowel diseases), the organ of vision (uveitis, iridocyclitis), musculoskeletal structures (high activity of psoriatic arthritis, osteoarthritis, uncontrolled against the background of basic therapy (clause 3 Inclusion criteria) ).
  • Major surgery (including joint surgery) within 8 weeks before the start of the study or elective surgery within 6 months after the start of the study.
  • A history of an adverse drug reaction to any of the components of the study drug or a reference drug.
  • Immunization with any live or live attenuated vaccine within 1 month before the first dose of the study drug or comparator drug.
  • A history of a disease associated with the accumulation of immune complexes that may distort the assessment of the effectiveness of ustekinumab therapy (including serum sickness, systemic lupus erythematosus, rheumatoid arthritis, polymyositis, scleroderma, Sjogren's syndrome, vasculitis, cryoglobulinemia).
  • Concomitant diseases and conditions that, in the opinion of the Investigator and/or Sponsor, jeopardize the safety of the patient during participation in the study, or which will influence the analysis of safety data.
  • Active systemic infection (bacterial, viral or fungal) within 14 days before signing the informed consent.
  • Pregnancy or breastfeeding.
  • History of tuberculosis, positive/doubtful result of screening for tuberculosis infection (tuberculosis allergen test or IGRA test or fluorography results). Inclusion of such patients is possible if effective specific treatment for tuberculosis infection has been carried out and there is a conclusion from a phthisiatrician about the possibility of ustekinumab therapy.
  • Participation in clinical trials of drugs less than 5 half-lives of the study drug before signing the informed consent.
  • Positive test for hepatitis B or C, HIV or syphilis.
  • Unwillingness or inability to comply with the recommendations prescribed by this protocol.
  • Identification during screening of other diseases/conditions not listed above that, in the opinion of the physician-researcher, prevent the inclusion of the patient in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: GNR-068 (JSC "GENERIUM", Russia)

Test drug

GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.

다른 이름들:
  • 우스테키누맙 바이오시밀러
활성 비교기: Stelara® (manufacturer Silag AG, Switzerland)

reference drug

Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.

다른 이름들:
  • 우스테키누맙

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The proportion of subjects with Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above
기간: Week 12

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 12

2차 결과 측정

결과 측정
측정값 설명
기간
The proportion of patients achieving PASI50/75/90/100
기간: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
Time to reach PASI50, PASI75, PASI90, PASI100
기간: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
Area under the curve (AUC) of PASI
기간: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
The proportion of partial responders (ie, patients achieving ≥50% but <75% improvement in PASI compared to baseline)
기간: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
Changes in the BSA index
기간: Week 60

Using the BSA (Body Surface Area) index, the surface area of the skin affected by psoriasis is assessed. BSA is measured in %. To determine the area of psoriatic skin lesions the "palm" rule is applicable. On the scalp, the affected area the size of one palm is assumed to be 10%, the torso - 3.3%, the upper extremities - 5%, the lower extremities - 2.5% of the area of the anatomical region of the body. To calculate the total BSA, each reported percentage must be multiplied by the corresponding factor of the corresponding body region (head = 0.1, torso = 0.3, upper extremities = 0.2, lower extremities = 0.4). The resulting four percentage values (percentage of skin affected by psoriasis on the scalp, upper extremities, trunk, and lower extremities) will be summed to estimate the BSA index.

Week 60
Changes in PGA
기간: Week 60

The PGA is 7-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).

Week 60
Changes in the intensity of itching on the visual analogue scale (VAS)
기간: Week 60

The intensity of itching is carried out at all visits using a visual analogue scale (VAS), where the left end of the line is 0 = no itching, the right end of the line is 10 = intense itching

Week 60
Changes in quality of life, assessed using the Dermatology Life Quality Index (DLQI)
기간: Week 60

The DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).

Week 60
The proportion of patients who dropped out of the study due to lack of sufficient therapeutic response
기간: Week 60

Treatment failure is assessed as no effect within 28 weeks (PASI response <50%)

Week 60

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 의자: Oksana A. Markova, MD, JSC GENERIUM

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 7월 25일

기본 완료 (실제)

2025년 4월 30일

연구 완료 (실제)

2025년 11월 26일

연구 등록 날짜

최초 제출

2024년 6월 28일

QC 기준을 충족하는 최초 제출

2024년 7월 3일

처음 게시됨 (실제)

2024년 7월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다